[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"melasma-facial-melasma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:melasma-facial-melasma":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,76,104,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100651951","efficacy-evaluation-of-a-cosmetic-product-for-facial-hyperpigmentation-100651951",false,"NCT07769268","Efficacy Evaluation of a Cosmetic Product for Facial Hyperpigmentation","Evaluation of the Efficacy of a Cosmetic Product for the Reduction of Facial Hyperpigmentation: A Clinical, Subjective, and Instrumental Study","HYPERPIG","Inclusion Criteria:\n\n* Female participants aged 30 to 60 years.\n* Group I: Participants with Fitzpatrick skin phototypes I to VI, with at least one participant from each phototype category. Participants with facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines.\n* Group II: Participants with moderate or greater melasma, as assessed by the modified Melasma Area and Severity Index (mMASI), and Fitzpatrick skin phototypes II to V.\n* Willingness to comply with all study procedures and attend scheduled on-site visits and assessments.\n* Willingness to comply with study procedures and be available for remote contact (telehealth) at scheduled times.\n* Ability to understand the study requirements, provide written informed consent, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study.\n* Use of anti-inflammatory, immunosuppressive, or antihistamine medications within 3 weeks prior to screening.\n* Skin conditions or marks in the study area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn.\n* History of atopic conditions or allergy to cosmetic products.\n* Active skin diseases and\u002For lesions in the assessment area.\n* Immunosuppression due to medication use or active disease.\n* Uncontrolled endocrine disorders.\n* Relevant medical history or current evidence of alcohol or substance abuse.\n* Known history or suspected intolerance to products of the same category as the study product.\n* Intense sun exposure within 15 days prior to assessment.\n* Aesthetic or dermatological treatments within 4 weeks prior to assessment.\n* Any other condition that, in the investigator's opinion, may interfere with study participation or justify exclusion from the study.",true,"FEMALE","30 Years","60 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","This is a single-center, single-blind clinical study designed to evaluate the efficacy of a depigmenting gel cream through clinical, subjective, and instrumental assessments. A total of 40 female participants, aged 30 to 60 years, will be enrolled and followed for 90 days while using the study product.Participants will be assigned to one of two groups. Group I will include 20 participants with facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines, representing Fitzpatrick skin phototypes I to VI, with at least one participant from each phototype. Group II will include 20 participants with moderate or greater melasma, as assessed by the modified Melasma Area and Severity Index (mMASI), representing Fitzpatrick skin phototypes II to V.\n\nThe study aims to evaluate the product's effectiveness in reducing facial hyperpigmentation and improving skin appearance over the treatment period.",[29,30],"Hyperpigmentation","Melasma (Facial Melasma)","RECRUITING","2026-08-17",{"date":34,"type":35},"2026-08-19","ACTUAL",{"date":37,"type":35},"2026-07-13",{"date":39,"type":23},"2027-01-21",{"name":41,"class":42},"Brainfarma Industria Química e Farmacêutica S\u002FA","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100649074","phase-4-oral-tranexamic-acid-plus-triple-combination-vs-triple-combination-alone-in-melasma-100649074","NCT07732192","Oral Tranexamic Acid Plus Triple Combination vs Triple Combination Alone in Melasma","Comparative Efficacy of Oral Tranexamic Acid With Triple Combination (Fluocinolone+ Hydroquinone +Tretinoin) Versus Triple Combination Alone in Melasma in a Tertiary Care Hospital","Inclusion Criteria: Patients aged 18 to 50 years of either gender with clinically diagnosed epidermal or mixed melasma of at least six months duration and baseline MASI score above the predefined threshold will be included. Patients willing to comply with treatment and follow-up schedule will be enrolled.\n\n\\-\n\nExclusion Criteria: Patients with dermal melasma, pregnancy, lactation, history of thromboembolic disease, coagulation disorders, current hormonal therapy use, recent treatment for melasma, hypersensitivity to study medications, or significant hepatic or renal disease will be excluded.\n\n\\-","ALL","18 Years","50 Years",{"count":55,"type":23},128,[57],"PHASE4","The data will be collected after the permission of the ethical committee of hospital. Following the enrollment, patients will be selected by lottery in the two equal groups. Group A will be administered with oral tranexamic acid and triple combination therapy whereas Group B will be treated with triple combination therapy. Strict use of sunscreens and sun protection will be promoted to all patients. Group A will administer oral tranexamic acid with the prescribed dose of the study drug along with topical application of fluocinolone acetonide, hydroquinone and tretinoin at bedtime. Group B will be treated by triple combination therapy only once a day at night. The study will continue to treatment. There will be a baseline MASI score which will be taken prior to the onset of treatment and re-evaluated at the planned follow-ups. The main outcome will be the decrease in the MASI score and the percentage of the patients who will be responding to treatment. The negative effects and recurrence in the follow-up will be considered as secondary outcomes. The structured proforma will gather data on age, gender, melasma duration, skin phototype, baseline MASI score, treatment group, follow-up MASI score, percentage improvement, adverse effects and treatment response. The principal investigator will document all the findings.",[60,30],"Melasma",[62,63,60,64],"Tranexamic Acid","MASI Score","Triple Combination Therapy","NOT_YET_RECRUITING","2026-07-23",{"date":68,"type":35},"2026-07-28",{"date":70,"type":23},"2026-07-15",{"date":72,"type":23},"2027-02-01",{"name":74,"class":75},"Combined Military Hospital Abbottabad","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":60,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":18,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":43},"100630292","comparative-evaluation-of-topical-30-metformin-and-kligmans-regimen-in-women-with-melasma-100630292","NCT07485777","Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Women With Melasma","A Novel Approach to Melasma Management: Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Middle-Aged Women","Inclusion Criteria:\n\n* Female patients aged 35-55 years\n* Clinically diagnosed epidermal or dermal melasma (confirmed by Wood's lamp examination)\n* Fitzpatrick skin types III-V\n* Duration of melasma ≥6 months\n* No topical or systemic treatment for melasma in the past month\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Known allergy to study medications\n* Active facial dermatitis, acne, or recent cosmetic procedures","35 Years","55 Years",{"count":86,"type":23},82,[26],"It's a prospective, randomised, assessor-blinded clinical study comparing topical 30% metformin with Kligman's regimen for melasma in women aged 35-55 years at Fauji Foundation Hospital, Rawalpindi. The study seeks to ascertain which treatment yields a more significant decrease in the modified MASI score over an 8-week period and which treatment is associated with fewer adverse effects, such as erythema, burning, peeling, and post-inflammatory hyperpigmentation. A total of 82 participants will be enrolled and randomly assigned to either metformin cream or Kligman's regimen, with both groups also using sunscreen. Assessments will be done at baseline, week 4, and week 8 through mMASI scoring, photographs, and side-effect monitoring. Data will be analyzed in SPSS 26 using t-tests and chi-square testing. The study is based on evidence suggesting metformin may offer comparable efficacy with better tolerability.",[30,60],[60,91,92,93,94],"topical metformin","kligman regimen","hyper-pigmentation","mMASI","2026-03-17",{"date":97,"type":35},"2026-03-20",{"date":99,"type":23},"2026-07-01",{"date":101,"type":23},"2027-06-01",{"name":103,"class":75},"Foundation University Islamabad",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":51,"minAge":111,"maxAge":84,"enrollmentInfo":112,"targetDuration":4,"studyType":24,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":43},"100608484","ultrasound-enhanced-delivery-of-compound-txa-solution-in-melasma-100608484","NCT07202156","Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma","Clinical Trial on the Efficacy and Safety of Ultrasound-Enhanced Delivery of Compound Tranexamic Acid Solution in the Treatment of Melasma","Inclusion Criteria:\n\n-(1) Male or female participants aged 20 to 55 years (inclusive); (2) Subjects clinically diagnosed with melasma and confirmed by the investigator to meet the trial requirements; (3) Subjects willing to comply with follow-up observations and able to provide portrait rights for documentation purposes; (4) Understanding and willingness to participate in the clinical trial, and voluntarily signing a written informed consent form.\n\nExclusion Criteria:\n\n* (1) Females who are pregnant, lactating, or planning to become pregnant during the trial period; (2) Subjects with known allergen to tranexamic acid or any excipient in the investigational product; (3) History of thrombosis or other thrombotic tendencies (e.g., hypertension, hyperlipidemia), or inability to discontinue oral contraceptives, estrogen, or prothrombin complex concentrates during the trial; (4) History of visual or ocular abnormalities (e.g. impaired vision, visual field defects, or fundus hemorrhage\u002Fedema) caused by abnormal retinal intravascular coagulation; (5) Patients with skin inflammation who have used topical steroid preparations for more than one month; (6) Presence of skin abnormalities at the trial site, such as nevi, ulcers, or erosions; (7) Any acute or chronic medical history (past or present) that may interfere with the validity or safety assessment of the trial; (8) Clinically significant abnormal laboratory test results prior to the trial; (9) Participation in any other clinical trial within 30 days prior to screening; (10) Any other condition deemed by the investigator to be unsuitable for participation in the study.","20 Years",{"count":113,"type":23},35,[26],"Melasma is a localized, acquired hyperpigmentary skin disorder characterized by well-defined, light to dark brown patches. Based on clinical practice and extensive literature reports, tranexamic acid and reduced Glutathione (GSH) are both applied in the treatment of melasma, but their water-soluble nature presents challenges for transdermal absorption. Our preliminary basic and clinical research has demonstrated that ultrasound-assisted delivery significantly enhances the absorption of tranexamic acid and other water-soluble components. Its effect on the skin barrier is temporary and reversible.\n\nThis study aims to evaluate the efficacy and safety of a compound solution (10% tranexamic acid, 2% GSH) delivered via ultrasound for melasma treatment through a split-face controlled trial.",[30],"2025-11-24",{"date":119,"type":35},"2025-11-25",{"date":121,"type":35},"2024-10-20",{"date":123,"type":23},"2026-02-25",{"name":125,"class":75},"The First Affiliated Hospital with Nanjing Medical University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":24,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":43},"100598428","comparison-of-a-cosmetic-serum-and-4-hydroquinone-for-treating-melasma-over-84-days-100598428","NCT07071363","COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYS","COMPARATIVE EVALUATION OF THE DERMATOLOGICAL TOLERANCE AND EFFICACY OF A COSMETIC SERUM VERSUS A 4% HYDROQUINONE-BASED PRODUCT IN SUBJECTS WITH MELASMA, AFTER 84 DAYS OF USE - STUDY CONDUCTED UNDER DERMATOLOGICAL SUPERVISION","Inclusion Criteria:\n\nMale or female subjects, primarily female, aged 18 to 65 years at the time of inclusion\n\nFitzpatrick skin phototype II to V\n\nDiagnosed with mild to moderate epidermal or mixed-type facial melasma, confirmed by Wood's lamp examination\n\nmMASI score between 3.5 and 13 at baseline\n\nSubject is in general good health as assessed by the investigator based on medical history and clinical examination\n\nWilling to avoid excessive sun exposure and use only the provided SPF50+ sunscreen during the study\n\nAble to understand the study procedures and provide written informed consent\n\nWilling and able to comply with study procedures and scheduled visits\n\nWomen of childbearing potential must agree to use a reliable method of contraception for at least 3 months prior to and during the entire study duration\n\nExclusion Criteria:\n\nPresence of post-inflammatory hyperpigmentation (PIH), lentigines, or other non-melasma facial pigmentation\n\nUse of topical or systemic depigmenting treatments, retinoids, corticosteroids, or hormonal treatments within 4 weeks prior to baseline\n\nKnown allergy or hypersensitivity to any component of the investigational or comparator products\n\nExcessive sun exposure or use of tanning beds within 2 weeks before baseline or planned during the study\n\nActive skin diseases (e.g., atopic dermatitis, psoriasis) or damaged skin in the test area\n\nPregnant or breastfeeding women, or those planning to become pregnant during the study\n\nParticipation in another clinical trial within 4 weeks prior to the study or planned participation in another trial during the study\n\nHistory of malignancy in the past 10 years (except treated basal cell carcinoma)\n\nUncontrolled systemic illness (e.g., diabetes, cardiovascular, hepatic, renal, or pulmonary disease)\n\nAny psychological or cognitive condition that would limit the subject's ability to understand the study procedures\n\nCurrent use of photosensitizing medications\n\nBMI \\> 40 or other conditions that may affect protocol compliance as judged by the investigator","65 Years",{"count":22,"type":23},[26],"The goal of this clinical trial is to compare the dermatological tolerance and skin-lightening efficacy of a cosmetic depigmenting serum to a 4% hydroquinone-based product in adult male and female subjects aged 18-65 years with mild to moderate epidermal or mixed-type melasma.\n\nThe main questions it aims to answer are:\n\nDoes the cosmetic serum reduce the severity of melasma (measured by mMASI) after 84 days of use?\n\nIs the cosmetic serum better tolerated than 4% hydroquinone under real-use conditions?\n\nResearchers will compare the serum group and the hydroquinone group to determine whether the cosmetic product achieves comparable pigmentation improvement with superior skin tolerability.\n\nParticipants will:\n\nGroup 1: Apply a morning routine (Depiwhite Serum + Depiwhite M SPF50+ cream) Apply an evening routine (Depiwhite Serum + Placebo Cream without Hydroquinone)\n\nGroup 2: Apply a morning routine (Serum Placebo + Depiwhite M SPF50+ cream) Apply an evening routine (Serum Placebo + Depigmenting Cream with hydroquinone 4%)\n\nVisit the clinical site at baseline (Day 0), Day 56, and Day 84 for assessments\n\nComplete standardized photographs, self-assessment questionnaires, and quality-of-life surveys (MELASQoL and ASLQI)\n\nUndergo clinical evaluations by a dermatologist, including mMASI scoring and tolerance assessment",[138,30,139],"Healthy","Epidermal Melasma",[60,141,142],"Hyperpigmentation Skin","Pigmentation Disorders","2025-08-15",{"date":145,"type":35},"2025-08-20",{"date":147,"type":35},"2025-06-23",{"date":149,"type":23},"2025-12-22",{"name":151,"class":42},"Laboratoire Dermatologique ACM"]